A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Clinical trial NCT02019277 · COMPLETED
Trial details
- NCT number
- NCT02019277
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-12-05
- Primary completion
- 2016-11-04
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.